% | $
Quotes you view appear here for quick access.

Pfizer Inc. Message Board

lokodaug 12 posts  |  Last Activity: Aug 28, 2015 7:15 PM Member since: Mar 26, 2014
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Generic comparison

    by bindroy Aug 28, 2015 10:50 AM
    lokodaug lokodaug Aug 28, 2015 7:15 PM Flag

    Rakoczy Molino Mazzochi Siwik LLP

    "Our experience is unparalleled in the industry. Since the firm’s inception in 2004, RMMS has handled over 240 Hatch-Waxman and related pharmaceutical litigation matters (including declaratory judgment, patent infringement, Administrative Procedure Act (APA), and commercial dispute matters) involving at least 130 different drug products for over 20 pharmaceutical clients. In addition to our substantial litigation experience, our attorneys also have extensive regulatory and legislative experience. Please visit our Profiles to learn more about the RMMS team"

    The meeting was about the Generic Epipen.....unless you are of the whogo mind set....

  • Reply to

    Generic comparison

    by bindroy Aug 28, 2015 10:50 AM
    lokodaug lokodaug Aug 28, 2015 7:04 PM Flag

    "Event Date : 08/07/2015 - 08/07/2015"
    "Location : Silver Spring, MD"
    "Subject : Mylan - EpiPen Meeting"

    And you get 3 greenies so far for being a would appear the 12 greenies for loko posts shows that some here have the intelligence to find the lokofacts when given hints....and some here have the intelligence to find whogo's fact-ory of oneliners of misinformation.............but everyone knows that whgo knows.......


  • Reply to

    Generic comparison

    by bindroy Aug 28, 2015 10:50 AM
    lokodaug lokodaug Aug 28, 2015 1:28 PM Flag

    yes cache, that was a very interesting meeting, mentioned it before but it went over like lead balloon filled with red thumbs.

    Hope you took time to research the players. The FDA officials were leaders in GENRIC drugs and the Hatch-Waxman agenda. The Mylan players were the number one and two guys. President of Corporations and president of the US division, plus a very other significant big shots. Google around the names, and there is some interesting stuff on everyone at the meeting. Several of the players from both sides were at the Hatch-Waxman 2015 gather this August. some good slides presented, and Mylan and Teva both presented at one conference on Hatch-Waxman, praising it.

    There is no doubt the meeting was a last ditch effort by Mylan, or at least to discuss the specifics on the upcoming Teva/ATRS Epipen Generic, the Epi-Instapen. ...but Pfizer gave it up years ago, they knew the Vibex Epinephrine was a winner and could not stop it, just slow it down....

    Anyhoot, good luck on your effort of presenting facts to this crowd.....big greenie for da effort....

    Gooo ATRS.......Generically kick an Epic Butt....

  • Reply to

    First to file generics market share(Teva EPI)

    by nammuang Aug 25, 2015 8:26 PM
    lokodaug lokodaug Aug 27, 2015 10:45 AM Flag

    Hey a futuristic cartoon alias it how would you know about BabyBalu....provide an old picture of it...there are several out there...but none on ATRS website....and yes and it is used in the fastest growing market out there, in need of a sweet AI....

    As for NF-QST.....would not be so negative about it....check out the newest worthless patent for Low-T...Sweet new stuff in it....

    Now if Jack would tell the ROW, life would be sweet again in ATRS la la land.........

    ATRS Rocks.......Eventually..... or sooner if James StockLasser and Scott Matsow come out of hiding and start pumping job again....U Go SA writers...Pump it Up! ....... Please....

  • Reply to

    First to file generics market share(Teva EPI)

    by nammuang Aug 25, 2015 8:26 PM
    lokodaug lokodaug Aug 25, 2015 9:44 PM Flag

    Oh no rymanola, nammu is much closer to being correct...30-40% easily of the US market only, from Day 1, Bang! ... Done deal, 3-4 million Epi-Instapens/yr..............then both Teva and Mylan markets will increase volume together but differently......until Teva goes ROW with the Epi-Instapen..........since that is why they also filed those pesky patent BabyBalu, WW......QST, WW........NF-QST, WW.........Qtrexup, ROW....

  • Reply to

    ROCHE ROBERT P JR bought another 5K at 1.77

    by rymankoly Aug 25, 2015 8:56 AM
    lokodaug lokodaug Aug 25, 2015 1:05 PM Flag

    Oh well thought insight on the newest AI patent and the EpiPen meeting was news worthy and conversational.....guess not....

    U Go Roche....way to find'em ryman..........

    So will just take the lokofacts and go home......again....

    But first......Hey stockdaugs......and U know..... what Jack knows... loko told ya so long ago, ....... that BabyBalu will Rock the Biologics.....

    ATRS Rocks .......from yet another untold, unknown, secret story.......but lokoknows...biologics.....sssshhhh, its a game......Aye Jack!

  • lokodaug lokodaug Aug 18, 2015 9:25 AM Flag

    Done loko's part.....complained and added some this point who cares anymore....just get the Epi-Instapen marketed and let loko get out of this POS.......

    Oh, and good job Mark. at least you try, unlike ATRS management and that PR guy, what's his name.....

  • A fun read....a month old, June 12, 2015

    "Opting for a generic EpiPen would seem to be a perfect solution for people faced with the high cost of this brand-name drug. Unfortunately, there is currently no generic version of this potentially life-saving injector."

    "A true generic Epipen may be available before the end of 2015, though it will largely depend on the manufacturer’s patents and FDA approval."

    "when a generic EpiPen becomes available, you can rest assured that you are getting a comparable medication at a much better price."

  • Reply to


    by batterupbymandm Aug 14, 2015 6:48 AM
    lokodaug lokodaug Aug 14, 2015 9:42 AM Flag

    "FDA accepted Teva's filing of an ANDA in October 2014 for exenatide..."

    And how long does it take for an ANDA approval?.....whogoknows......and lokoknows nothing that is correct....but it is nice to see loko was right on exenatide and........

    As far as when something gets marketed, who the forkinknows.....ATRS is suppose to be a well oiled 505 (b) (2) generating machine.....according to products would be flying out the door every they must be getting stuck and pilling up, and will all come bursting out any picosecond now ........POW .............snore......Zzzzzz......dreaming of 30 months for a new product.....

  • Exactly what was pointed out earlier.....Teva needs to get the AB rating before the school year starts....Come on just once get some great news....everything just drags, on and on and on with ATRS.....

    "This is the only program of its kind supporting access to epinephrine in the event a person experiences a life-threatening allergic reaction, or anaphylaxis, in the school setting. Since its launch in August 2012, more than 56,000 schools have participated in the program."

    As we reflect on the first three years of the program, we are proud of the progress made to enhance anaphylaxis preparedness in schools across the country," said Mylan CEO, Heather Bresch. "With more than 56,000 schools enrolled to date, we often hear about the impact this program has had in local communities. Up to 25% of anaphylaxis cases at school occur in those who have not been previously diagnosed with a life-threatening allergy, so we encourage eligible schools to enroll before students return this fall."

    An exploratory, web-based survey of more than 6,000 schools participating in the EpiPen4Schools® program during the 2013/2014 school year found there were a total of 919 anaphylactic events among students and staff at 607 schools. In those events when an epinephrine auto-injector was used, nearly half (48.7%) were treated with an EpiPen® Auto-Injector provided by the EpiPen4Schools® program.

    "This past school year, EpiPen® Auto-Injectors provided by the EpiPen4Schools® program were used in two incidents," said Connie Trent, RN, BSN, Health Services Facilitator, Forsyth County Schools, Cumming, Ga. "It is of utmost importance that school personnel are able to act quickly, and with the support and training resources provided through EpiPen4Schools®, our staff is prepared to respond."

  • "The EpiPen is used for emergency treatment of life-threatening allergic reactions. Mylan reiterated Thursday that it expects generic competition for EpiPen starting in the second half of this year."

    "Second-quarter sales for Mylan’s specialty division, predominantly made up of EpiPen, rose 5 percent from a year earlier to $301.9 million. Leerink Partners analyst Jason Gerberry had expected sales of $275 million."

    Any day Epic POW.....

  • Reply to

    Uhm... Are We

    by elmer92692 Jun 2, 2015 4:50 PM
    lokodaug lokodaug Jun 2, 2015 10:28 PM Flag

    nammu whogo is pulling your leg, he never talked to loko last night....

32.43-0.23(-0.70%)10:07 AMEDT